Viking Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, VKTX, Viking Therapeutics Inc, priceseries

Viking Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
3.25
Close
3.11
High
3.25
Low
3.11
Previous Close
3.18
Daily Price Gain
-0.07
YTD High
4.92
YTD High Date
Jan 3, 2022
YTD Low
3.04
YTD Low Date
Feb 24, 2022
YTD Price Change
-1.77
YTD Gain
-36.27%
52 Week High
7.20
52 Week High Date
Sep 2, 2021
52 Week Low
3.04
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-3.32
52 Week Gain
-51.63%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 30. 2016
1.19
Jan 13. 2017
1.38
9 Trading Days
15.55%
Link
LONG
Sep 7. 2017
1.12
Oct 16. 2017
2.04
27 Trading Days
81.90%
Link
LONG
Jan 2. 2018
4.48
Jan 12. 2018
4.79
8 Trading Days
7.02%
Link
LONG
Feb 1. 2018
5.31
Feb 27. 2018
6.28
17 Trading Days
18.33%
Link
LONG
May 31. 2018
9.99
Jun 1. 2018
10.58
1 Trading Days
5.91%
Link
LONG
Aug 22. 2018
10.45
Sep 5. 2018
11.74
9 Trading Days
12.35%
Link
LONG
Mar 28. 2019
8.51
Apr 11. 2019
10.02
10 Trading Days
17.72%
Link
LONG
Dec 6. 2019
7.34
Dec 20. 2019
7.83
10 Trading Days
6.71%
Link
LONG
May 8. 2020
6.52
May 27. 2020
7.45
12 Trading Days
14.27%
Link
LONG
Nov 3. 2020
5.79
Dec 1. 2020
6.34
19 Trading Days
9.53%
Link
LONG
Feb 2. 2021
7.67
Feb 12. 2021
8.55
8 Trading Days
11.52%
Link
LONG
Jun 7. 2021
5.50
Jun 29. 2021
6.25
16 Trading Days
13.67%
Link
Company Information
Stock Symbol
VKTX
Exchange
NasdaqCM
Company URL
http://www.vikingtherapeutics.com
Company Phone
858-704-4660
CEO
Brian Lian
Headquarters
California
Business Address
12340 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA 92130
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001607678
About

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for metabolic and endocrine disorders. Its clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. The company also focuses on the development of small molecule agonists of the thyroid receptor beta for adrenoleukodystrophy and lipid disorders such as hypercholesterolemia and non-alcoholic steatohepatitis. Viking Therapeutics was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which is in a Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading